Volume 21, Number 3—March 2015
Research
Risk Factors for Death from Invasive Pneumococcal Disease, Europe, 2010
Table 1
Characteristic | No. cases (% of total), N = 17,549 | Sample size, no. (%), n = 2,921† |
---|---|---|
Sex | ||
F | 7,915 (45.3) | 1,257 (43.2) |
M
|
9,565 (54.7)
|
1,651 (56.8)
|
Age group, y | ||
<5 | 1,980 (11.3) | 570 (19.7) |
5–64 | 7,819 (44.7) | 1,222 (42.1) |
>65
|
7,684 (44.0)
|
1,108 (38.2)
|
Outcome | ||
Nonfatal | 4,146 (89.4) | 2,657 (91.0) |
Fatal
|
491 (10.6)
|
264 (9.0)
|
Clinical presentation | ||
Nonmeningitis | 6,047 (79.4) | 1,722 (81.5) |
Meningitis
|
1,572 (20.6)
|
391 (18.5)
|
Serotype | ||
PCV13-specific‡ | 4,185 (42.1) | 1,235 (42.7) |
PCV7 | 1,772 (17.8) | 517 (17.9) |
Non-PCV
|
3,989 (40.1)
|
1,169 (40.0)
|
Antimicrobial susceptibility | ||
Penicillin | ||
Susceptible | 8,420 (91.1) | 1,949 (94.1) |
Nonsusceptible§ | 827 (8.9) | 122 (5.9) |
Erythromycin | ||
Susceptible | 6,911 (82.5) | 1,573 (76.4) |
Nonsusceptible | 1,471 (17.5) | 486 (23.6) |
*Numbers do not add to the total in each category because of missing data. See Figure 1. PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV.
†Defined as patients for whom information was available about serotype and outcome.
‡Serotypes contained in PCV13 but not in PCV7.
§Either resistant or intermediate resistance.
1Members of the Invasive Pneumococcal Disease Study Group who contributed data are listed at the end of this article.
Page created: April 16, 2015
Page updated: April 16, 2015
Page reviewed: April 16, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.